ArticleProceedings of the National Academy of Sciences of the United States of America2006
Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 89 citations in OpenAlex.
- Exploring recent progress of molecular farming for therapeutic and recombinant molecules in plant systems.Heliyon · 2024Review
- Immunotherapeutic effects of recombinant colorectal cancer antigen produced in tomato fruits.Scientific reports · 2022Article
- Functional Characterization of Pembrolizumab Produced inFrontiers in plant science · 2021Article
- Optimization of the human colorectal carcinoma antigen GA733-2 production in tobacco plants.Plant biotechnology reports · 2021Article
- Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production.Plants (Basel, Switzerland) · 2020Review
- The M4 insulator, the TM2 matrix attachment region, and the double copy of the heavy chain gene contribute to the enhanced accumulation of the PHB-01 antibody in tobacco plants.Transgenic research · 2020Article
- Expression and In Vitro Function of Anti-Breast Cancer Llama-Based Single Domain Antibody VHH Expressed in Tobacco Plants.International journal of molecular sciences · 2020Article
- Structural and In Vitro Functional Analyses of Novel Plant-Produced Anti-Human PD1 Antibody.Scientific reports · 2019Article
- Reconceptualizing cancer immunotherapy based on plant production systems.Future science OA · 2017Review
- Production of Recombinant Anti-Cancer Vaccines in Plants.Biomolecules & therapeutics · 2017Review
- Plantibodies in human and animal health: a review.African health sciences · 2016Review
- Production of monoclonal antibodies in plants for cancer immunotherapy.BioMed research international · 2015Review
- Expression of recombinant vaccines and antibodies in plants.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2014Review
- Intracellular reprogramming of expression, glycosylation, and function of a plant-derived antiviral therapeutic monoclonal antibody.PloS one · 2013Article
- Expression of GA733-Fc fusion protein as a vaccine candidate for colorectal cancer in transgenic plants.Journal of biomedicine & biotechnology · 2012Article
- Evolution of plant-made pharmaceuticals.International journal of molecular sciences · 2011Review
- Different subcellular localization and glycosylation for a functional antibody expressed in Nicotiana tabacum plants and suspension cells.Transgenic research · 2009Article
- Identification of mRNA splicing factors as the endothelial receptor for carbohydrate-dependent lung colonization of cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Article
- Plant-derived EpCAM antigen induces protective anti-cancer response.Cancer immunology, immunotherapy : CII · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although current demands for therapeutic mAbs are growing quickly, production methods to date, including in vitro mammalian tissue culture and transgenic animals, provide only limited quantities at high cost. Several tumor-associated antigens in tumor cells have been identified as targets for therapeutic mAbs. Here we describe the production of mAb BR55-2 (IgG2a) in transgenic plants that recognizes the nonprotein tumor-associated antigen Lewis Y oligosaccharide overexpressed in human carcinomas, particularly breast and colorectal cancers. Heavy and light chains of mAb BR55-2 were expressed separately and assembled in plant cells of low-alkaloid tobacco transgenic plants (Nicotiana tabacum cv. LAMD609). Expression levels of plant-derived mAb (mAbP) were high (30 mg/kg of fresh leaves) in T1 generation plants. Like the mammalian-derived mAbM, the plant mAbP bound specifically to both SK-BR3 breast cancer cells and SW948 colorectal cancer cells. The Fc domain of both mAbP and mAbM showed the similar binding to FcgammaRI receptor (CD64). Comparable levels of cytotoxicity against SK-BR3 cells were also shown for both mAbs in antibody-dependent cell-mediated cytotoxicity assay. Furthermore, plant-derived BR55-2 efficiently inhibited SW948 tumor growth xenografted in nude mice. Altogether, these findings suggest that mAbP originating from low-alkaloid tobacco exhibit biological activities suitable for efficient immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.